The Cancer Imaging Shared Resource was established realizing that recent advances in imaging provide a means of translating our understanding of the molecular or cellular changes associated with malignancy to studies performed in the living organism. The Cancer Imaging Shared Resource provides investigators with support and training to accelerate and refine integrative studies in animal models of human cancer. This goal is accomplished by providing equipment, training and assistance to investigators conducting studies using advanced molecular imaging approaches, including the instrumentation, molecular probes and reporter genes necessary for conducting these studies. The goal is to advance the understanding of the molecular basis of cancer and to discover novel therapeutic approaches. This Shared Resource adds value by bringing together imaging expertise and state-of-theart imaging equipment and techniques. The Shared Resource complements the Cancer Imaging Research Program (Program 4) as well as other Programs including: Cancer Biology (Program 1), Radiation Biology (Program 2), Cancer Stem Cells (Program 3), Lymphoma and Hodgkin's Disease (Program 6), Cancer Immunology and Immunotherapy (Program 7), and Hematopoetic Cell Transplantation and Immune Reconstitution (Program 8). The Shared Resource works closely with investigators to advance new imaging technologies and to translate advances made in this program to all of the investigators in the Cancer Center. As applications of these technologies to cancer studies are demonstrated and standardized, usage among Cancer Center members is expected to increase dramatically. Future plans include the expansion of available instrumentation and addition of new features to existing equipment, providing additional avenues for cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-02
Application #
7623564
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
2
Fiscal Year
2008
Total Cost
$61,167
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Im, Hogune; Rao, Varsha; Sridhar, Kunju et al. (2018) Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells. Leuk Lymphoma 59:2952-2962
Huang, Min; Zhu, Li; Garcia, Jacqueline S et al. (2018) Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget 9:11665-11676
Chiou, Shin-Heng; Dorsch, Madeleine; Kusch, Eva et al. (2018) Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 8:14008
Breslow, David K; Hoogendoorn, Sascha; Kopp, Adam R et al. (2018) A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Nat Genet 50:460-471
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442
Gee, Marvin H; Han, Arnold; Lofgren, Shane M et al. (2018) Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell 172:549-563.e16
Malta, Tathiane M; Sokolov, Artem; Gentles, Andrew J et al. (2018) Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173:338-354.e15

Showing the most recent 10 out of 322 publications